Efficacy and Safety of Varenicline Among HIV-infected Patients
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
Cigarette smoking is a major cause of illness among HIV-infected patients (non-AIDS defining
malignancies (especially lung cancer), non-AIDS bacterial infections and cardio-vascular
diseases). Approximately 50% of HIV-infected patients are regular tobacco smokers. Tobacco
smoking cessation has well known benefits on mortality and morbidity in the general
population where tobacco cessation assistance programs are increasingly implemented. However,
smoking cessation interventions have never been evaluated among HIV-infected patients. This
trial aims at evaluating the efficacy and safety of varenicline for smoking cessation
compared with placebo.
Phase:
Phase 3
Details
Lead Sponsor:
ANRS, Emerging Infectious Diseases French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)